Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on CVS Caremark Corporation

Related CVS
Early Global News: Record Online Sales, 400% Jump In Tinder Users, China Experiences Worst Drop In Months
CVS Health Announces Formulary and Therapy Strategy for PCSK9 Inhibitors
The Catalyst That Antares Pharma Really Needs To See Growth (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on CVS Caremark Corporation (NYSE: CVS), and raised its price target from $50.00 to $54.00.

Jefferies noted, “CVS reported another strong Q fulfilling our 2012 thesis that it would beat and raise throughout the year. The looming question is what CVS will do for an encore. While compares get more difficult, CVS' advantaged business model, significant cash flow and strong management team suggest FY13 will be another successful year, likely driven by a number of smaller catalysts. This, plus a modest valuation, implies the equity is undervalued.”

CVS Caremark Corporation closed on Tuesday at $46.88.

Latest Ratings for CVS

Nov 2015JP MorganMaintainsOverweight
Nov 2015OppenheimerMaintainsOutperform
Aug 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (CVS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters